Jun. 23 at 12:03 PM
Canaccord Genuity reiterated
$VTYX Buy-
$14 after Ventyx reported positive results from the Phase lla open-label study for VTX3232 in early Parkinson's
disease (PD).
$VIGL -
$SNY
Canaccord Genuity said in its note;
"The trial's positive results demonstrated effective inhibition of NLRP3 and suppression of downstream biomarkers. Results from the trial support once-daily dosing. Ventyx plans to initiate a Phase II dose-ranging study for the drug in patients with Parkinson's.
We are encouraged by the reported results from the Phase lla trial, and we believe the study results support a potential indication of VTX3232 in additional neurodegenerative diseases. We remain bullish on shares of
$VTYX and reiterate our
$14 12-month PT."
